Covered recipient · General Payments record
JAMIE P OLENEC
Allopathic & Osteopathic Physicians Allergy & Immunology
General Payments · PY2018–2024
$917.36
- Reported across 41 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $339.59 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $135.73 | 8 |
| GlaxoSmithKline, LLC. | $129.43 | 5 |
| Amgen Inc. | $26.85 | 1 |
| ABBVIE INC. | $25.26 | 1 |
| BioCryst US Sales Co., LLC | $22.32 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $25.26 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105151545 | CMS |
| Amgen Inc. | $26.85 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111665526 | CMS |
| BioCryst US Sales Co., LLC | $22.32 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117480416 | CMS |
| GENZYME CORPORATION | $27.29 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139768662 | CMS |
| GENZYME CORPORATION | $5.00 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139768704 | CMS |
| GENZYME CORPORATION | $30.80 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139768700 | CMS |
| GENZYME CORPORATION | $7.25 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139768702 | CMS |
| GENZYME CORPORATION | $8.59 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139768698 | CMS |
| GENZYME CORPORATION | $8.61 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139768696 | CMS |
| GENZYME CORPORATION | $39.39 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139768732 | CMS |
| GENZYME CORPORATION | $8.80 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139768742 | CMS |
| GlaxoSmithKline, LLC. | $33.82 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115880868 | CMS |
| GlaxoSmithKline, LLC. | $24.96 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116409325 | CMS |
| GlaxoSmithKline, LLC. | $22.54 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116434196 | CMS |
| GlaxoSmithKline, LLC. | $24.36 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116720216 | CMS |
| GlaxoSmithKline, LLC. | $23.75 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116576214 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.